Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause (VABIP)
Genitourinary Syndrome of Menopause, Postmenopausal Disorder, Menopause
About this trial
This is an interventional treatment trial for Genitourinary Syndrome of Menopause focused on measuring Polynucleotides, Genitourinary syndrome of menopause, Postmenopause, Vagina atrophy, Vaginal biorevitalization
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Genitourinary Syndrome of Menopause that presents an MRS > 5 in the urogenital domain, with alterations in the vaginal maturity index (VMI) and in the vaginal pH
Exclusion Criteria:
- Incomplete clinical records or clinical records.
- Age over 70 years.
- Diagnosis of secondary (hereditary) osteoporosis.
- History of prolonged use of steroids.
- Lack of adherence to medical treatment.
- Diagnosis of cancer.
- Diagnosis of depression.
- Diagnosis of Celiac disease or with the presence of alterations in intestinal absorption.
- Allergies to any of the medications administered.
Sites / Locations
- Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Polynucleotide vaginal suppositories
Conjugated estrogens cream
In this arm 72 first-time participants of the "peri-postmenopause and bone metabolism clinic" of the "Regional Hospital October 1st " of ISSSTE Mexico, were randomly enrolled to be treated with local salmon polydeoxyribonucleotide (PDRN) therapy.
In this arm 64 first-time participants of the "peri-postmenopause and bone metabolism clinic" of the "Regional Hospital October 1st " of ISSSTE Mexico, were randomly enrolled to be treated with the gold-standard treatment with local estrogen-based hormone therapy.